I'm Confused... Are Arthritis Medicines Good for Me or Bad for Me?

Non-steroidal anti-inflammatory drugs (NSAIDS) are a mainstay of arthritis treatment. However, recent concerns regarding their cardiovascular safety make their routine use in arthritis therapy problematic.

NSAIDs possess a certain risk for kidney toxicity which contributes to fluid retention and edema while also promoting the aggravation of hypertension.

However, often underappreciated are the blood pressure and kidney effects of NSAIDs. It has long been noted that a potential risk of NSAIDs is a destabilization of blood pressure control in hypertensive patients, particularly if they are treated with ACE inhibitors.

Direct kidney toxicity, deleterious changes in kidney blood flow, and decline in kidney function are seen as a consequence in patients treated with NSAIDs. Edema and worsening of congestive heart failure (CHF) are also potential known consequences of NSAIDs. NSAIDs may also interfere with the cardioprotective effects of aspirin.

However... all is not doom and gloom for NSAIDS.

A study of Medicare patients with osteoarthritis provides additional evidence that non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin reduce the risk of colorectal cancer. Earlier investigations of the drugs'' impact on tumor development could not rule out the possibility that an observed protective effect was caused by other preventive health care measures. Researchers note, however, that safer drugs are probably needed before regular preventive therapy can be recommended.

Elizabeth Lamont, MD, MS, of the Massachusetts General Hospital Cancer Center, the study''s lead author, states, "Although patients face risks such as bleeding or kidney damage from NSAIDS, they probably are at a lower risk of developing colorectal cancer." Because of the risks posed by the dosage used to treat osteoarthritis, she stresses that currently available NSAIDs should not be used solely to prevent cancer.

Earlier randomized trials indicated that NSAID treatment could possibly prevent the development of precancerous colorectal polyps, but whether or not such therapy also reduces the risk of invasive colorectal cancer has not yet been confirmed. Those trials used relatively low doses of aspirin and showed no significant differences in colorectal cancer rates between the aspirin and placebo groups. While many observational studies have shown a protective effect of NSAIDs against colorectal cancer, interpretation of some of those results may have been clouded by other healthy behaviors of the participants.

First, the researchers reviewed data from the 1993-94 National Ambulatory Medical Care Survey, in which physicians report on the diagnoses of and treatments prescribed to patients seen during a randomly selected week. Those results verified that older patients with osteoarthritis were more than four times as likely to take NSAIDs as were those without osteoarthritis. They then analyzed information from the Survival Epidemiology and End-Results (SEER)-Medicare program, studying groups of elderly Medicare patients with and without colorectal cancer, to search for associations with NSAID use.

Comparing information on 4,600 individuals with colorectal cancer to data from 100,000 controls, they found that a history of osteoarthritis was associated with a 15 percent reduction in the likelihood of a colorectal cancer diagnosis.

"The magnitude of colorectal cancer risk reduction between patients with and without osteoarthritis is completely consistent with the risk reduction for pre-cancerous polyps reported in clinical trials of NSAIDs," Lamont says.

The study appears in the August 2007 Journal of General Internal Medicine.

The study also raises the 64 dollar question which is "What is the risk/benefit of taking an NSAID for cancer prevention versus the risk of cardiovascular side-effects?

As a practicing rheumatologist, I am in a constant battle with cardiologists who want to stop NSAID therapy. In addition to quality of life issues, this most recent study also raises another issue- that of possible colon cancer prevention.

athan Wei, MD FACP FACR is a rheumatologist and Director of the Arthritis and Osteoporosis Center of Maryland. He is a Clinical Assistant Professor of Medicine at the University of Maryland School of Medicine. For more info: Arthritis Treatment